Regeneron Pharmaceuticals
REGN
$12.32 (1.16%)
1D
1W
3M
1Y
5Y
ALL
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious diseases. The Company's commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. It is also engaged in the research, development of monoclonal antibodies, which consists of Dupixent, Kevzara, and itepekimab. The Company's marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, Kevzara (sarilumab) Solution for Subcutaneous Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
Zacks Investment Research • 3 hours ago • REGN
Regeneron (REGN) Earnings Expected to Grow: Should You Buy?Accesswire • 1 day ago • REGN
Regeneron Pharmaceuticals Inc Investors With Losses Are Encouraged To Contact The Schall Law Firm As They Initiate An Investigation Into AllegationsAccesswire • 2 days ago • REGN
Regeneron Pharmaceuticals Inc Investors With Losses Are Encouraged To Contact The Schall Law Firm As They Initiate An Investigation Into AllegationsAccesswire • 3 days ago • REGN
Regeneron Pharmaceuticals Inc Investors With Losses Are Encouraged To Contact The Schall Law Firm As They Initiate An Investigation Into AllegationsZacks Investment Research • 3 days ago • REGN
HRMY or REGN: Which Is the Better Value Stock Right Now?Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.